Ramipril - Hypertension

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

Mean values of systolic and diastolic office blood pressure

Secondary objectives:

Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Ramipril

Criteria

Inclusion Criteria:

• no previous antihypertensive therapy

• high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

Exclusion Criteria:

• antihypertensive therapy

• blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg